放射性核素治疗共识命名:核医学全球倡议的初步推荐
核医学全球倡议(NMGI)针对系统性放射性核素治疗术语不统一的问题,向成员组织发放在线调查,收集30个国家240份回答,52%受访者偏好「靶向放射性核素治疗」,约37%偏好「放射性药物治疗」,11%偏好「分子放射性核素治疗」,并就相关关键术语达成共识讨论。
要点
- 调查覆盖30个国家240名医师、物理师、科学家等多学科人员。
- 52%受访者偏好「靶向放射性核素治疗」作为放射性核素治疗的统称。
- 约37%偏好「放射性药物治疗」,11%偏好「分子放射性核素治疗」。
核心结论
- NMGI制定系统性放射性核素治疗统一命名的初步推荐,以改善领域内沟通、反映所用技术、便于结果比较并最终改善患者结局。
研究设计与样本
- 核医学全球倡议(NMGI)在线调查,面向NMGI成员组织,覆盖多地域多学科,共收集30个国家240份匿名回答。
主要发现
- 调查显示「靶向放射性核素治疗」被普遍用于指代放射性核素治疗,52%受访者偏好该术语。
- 约37%受访者偏好「放射性药物治疗」,11%偏好「分子放射性核素治疗」。
- 在靶向放射性核素治疗 umbrella 下的其他关键术语也进行了讨论以达成术语共识。
关键数值与推荐
- 52%受访者偏好「靶向放射性核素治疗」。
- 约37%受访者偏好「放射性药物治疗」。
- 11%受访者偏好「分子放射性核素治疗」。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since its inception in 2012, the Nuclear Medicine Global Initiative (NMGI) of the Society of Nuclear Medicine and Molecular Imaging has played an important role in addressing significant challenges in the field of nuclear medicine and molecular imaging. The first 3 projects were dedicated to standardizing pediatric nuclear medicine practices, addressing the global challenges of radionuclide access and availability, and assessing the educational and training initiatives on theranostics across the globe. These efforts aimed to advance human health, foster worldwide educational collaboration, and standardize procedural guidelines to enhance quality and safety in nuclear medicine practice. In its latest project, NMGI aimed to develop a unified nomenclature for systemic radionuclide therapy in nuclear medicine, addressing the diverse terminology currently used. An online survey was distributed to NMGI member organizations, drawing participation from various geographical locations and disciplines. The survey anonymously collected responses from physicians, physicists, scientists, radiopharmacists, radiopharmaceutical scientists, dosimetrists, technologists, and nurse managers, totaling 240 responses from 30 countries. Findings revealed a prevailing use of the term targeted radionuclide therapy for radionuclide therapy, with 52% of respondents expressing a preference for this term. In contrast, approximately 37% favored "radiopharmaceutical therapy," whereas 11% favored "molecular radionuclide therapy." Other key terms under the umbrella of targeted radionuclide therapy were also discussed to achieve a consensus on terminology. NMGI efforts to standardize terminology in this dynamic and fluid field should improve communication within the field, better reflect the technology used, enable comparison of results, and ultimately lead to improved patient outcomes.
引用
- Al-Ibraheem A, Scott AM, Abdlkadir AS, et al. Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative. J Nucl Med. 2025. PMID: 40147850. doi:10.2967/jnumed.124.269215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。